November 16, 2026 · Blood · DOI: 10.1182/blood.2026035635

Carfilzomib-based strategies in transplant-eligible multiple myeloma: long-term follow-up of the phase 2 FORTE trial.

Listen to this summary

The FORTE phase 2 trial asked whether carfilzomib-based induction followed by autologous stem cell transplantation (KRd-ASCT) and carfilzomib-lenalidomide maintenance (KR) improve long-term outcomes in transplant-eligible newly diagnosed multiple myeloma. With a median follow-up of about 8 years, KRd-ASCT significantly extended progression-free survival compared with KRd alone for 12 cycles or KCd-ASCT (median PFS 98 vs 70 and 67 months), and KR maintenance improved PFS versus lenalidomide alone, with MRD negativity linked to prolonged benefit. The authors conclude that these long-term results confirm the high effectiveness of KRd-ASCT followed by KR maintenance, with a second primary malignancy incidence of 6%.

Giuseppe Bertuglia, Mattia D'Agostino, Delia Rota-Scalabrini, Angelo Belotti, Laura Paris, Micol Quaresima, Sonia Morè, Stelvio Ballanti, Sara Aquino, Paolo De Fabritiis, Francesca Fioritoni, Michele Cea, Nicola Giuliani, Francesca Patriarca, Stefania Oliva, Massimo Gentile, Francesca Fazio, Renato Zambello, Sara Bringhen, Paolo Corradini, Benedetto Bruno, Elena Zamagni, Mario Boccadoro, Pellegrino Musto, Francesca Gay

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play